685 U.S. HIGHWAY ONE, 2ND FLOOR, NORTH BRUNSWICK, NJ
Material disclosure
Corporate Presentation NASDAQ: ANL
Management Change
Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Reports Unaudited First Half 2025 Financial Results and Highlights Recent Operational Progress
Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Extraordinary General Meeting Results
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
No filings found
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Prospectus filed pursuant to Rule 424(b)(7)
Submission Upload
Correspondence